ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för rifaximin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

33 träffar

Bibliografisk träff 2015-09-01

Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.

Khokhar N, Qureshi MO, Ahmad S, Ahmad A, Khan HH, Shafqat F, Salih M.

J Gastroenterol Hepatol · comparative study; randomized controlled trial; journal article · DOI 10.1111/jgh.12970

Bibliografisk träff 2015-07-01

Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.

Gangarapu V, Ince AT, Baysal B, Kayar Y, Kılıç U, Gök Ö, Uysal Ö, Şenturk H.

Eur J Gastroenterol Hepatol · research support, non-u.s. gov't; journal article; observational study · DOI 10.1097/meg.0000000000000348

Bibliografisk träff 2015-05-13

Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.

Bae S, Lee KJ, Kim YS, Kim KN.

J Korean Med Sci · controlled clinical trial; research-article; journal article · DOI 10.3346/jkms.2015.30.6.757

Bibliografisk träff 2015-03-01

The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.

Mostafa T, Badra G, Abdallah M.

Turk J Gastroenterol · randomized controlled trial; journal article · DOI 10.5152/tjg.2015.7782

Bibliografisk träff 2015-02-15

Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.

Zhang Y, Feng Y, Cao B, Tian Q.

Int J Clin Exp Med · research-article; journal article

Bibliografisk träff 2015-02-01

Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.

Laterza L, Ianiro G, Scoleri I, Landi R, Bruno G, Scaldaferri F, Gaetani E, Campanale M, Gasbarrini A, Gasbarrini A.

Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2015.1007951

Bibliografisk träff 2015-01-13

Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes.

Courson A, Jones GM, Twilla JD.

J Pharm Pract · comparative study; journal article · DOI 10.1177/0897190014566312

Bibliografisk träff 2014-12-16

Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.

Blandizzi C, Viscomi GC, Scarpignato C.

Drug Des Devel Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.2147/dddt.s72572

Bibliografisk träff 2014-10-22

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis.

Bajaj JS, Barrett AC, Bortey E, Paterson C, Forbes WP.

Aliment Pharmacol Ther · research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1111/apt.12993

Bibliografisk träff 2014-09-11

Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.

Tenorio AR, Chan ES, Bosch RJ, Macatangay BJ, Read SW, Yesmin S, Taiwo B, Margolis DM, Jacobson JM, Landay AL, Wilson CC, A5286 Team.

J Infect Dis · research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1093/infdis/jiu515

Bibliografisk träff 2013-07-26

Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis.

Schrodt C, McHugh EE, Gawinowicz MA, Dupont HL, Brown EL.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0068550

Bibliografisk träff 2013-07-23

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK.

Am J Gastroenterol · comparative study; randomized controlled trial; journal article · DOI 10.1038/ajg.2013.219

Bibliografisk träff 2013-07-09

Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates.

Gomes C, Ruiz L, Pons MJ, Ochoa TJ, Ruiz J.

Trans R Soc Trop Med Hyg · research support, non-u.s. gov't; journal article · DOI 10.1093/trstmh/trt059

Bibliografisk träff 2013-06-24

Proteome profiles of vaginal fluids from women affected by bacterial vaginosis and healthy controls: outcomes of rifaximin treatment.

Cruciani F, Wasinger V, Turroni S, Calanni F, Donders G, Brigidi P, Vitali B.

J Antimicrob Chemother · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/jac/dkt244

Bibliografisk träff 2013-05-01

Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation.

Qayed M, Langston A, Chiang KY, August K, Hilinski JA, Cole CR, Rogatko A, Bostick RM, Horan JT.

J Pediatr Hematol Oncol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1097/mph.0b013e31827e56af

Bibliografisk träff 2013-05-01

Toxic epidermal necrolysis associated with rifaximin.

Patel AS, Supan EM, Ali SN.

Am J Health Syst Pharm · journal article; case reports · DOI 10.2146/ajhp120137

Bibliografisk träff 2013-05-01

Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.

Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundarò C, Gasbarrini A.

Eur Rev Med Pharmacol Sci · clinical trial; research support, non-u.s. gov't; journal article

Bibliografisk träff 2013-04-16

The effect of rifaximin on gut flora and Staphylococcus resistance.

Kim MS, Morales W, Hani AA, Kim S, Kim G, Weitsman S, Chang C, Pimentel M.

Dig Dis Sci · research support, non-u.s. gov't; evaluation study; journal article · DOI 10.1007/s10620-013-2675-0

Bibliografisk träff 2013-04-03

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis.

Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY.

Gastroenterol Res Pract · research-article; journal article · DOI 10.1155/2013/236963

Bibliografisk träff 2013-04-02

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM.

PLoS One · clinical trial; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0060042

Bibliografisk träff 2013-03-25

Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin.

Lutz P, Parcina M, Bekeredjian-Ding I, Hoerauf A, Strassburg CP, Spengler U.

Infection · journal article; case reports · DOI 10.1007/s15010-013-0449-4

Bibliografisk träff 2013-03-01

Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.

Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD.

J Gastroenterol Hepatol · controlled clinical trial; journal article · DOI 10.1111/jgh.12070

Bibliografisk träff 2013-03-01

Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?

Farrell DJ.

J Clin Gastroenterol · review; journal article · DOI 10.1097/mcg.0b013e31827559a3

Bibliografisk träff 2013-03-01

The role of antimicrobials in Crohn's disease.

Kale-Pradhan PB, Zhao JJ, Palmer JR, Wilhelm SM.

Expert Rev Gastroenterol Hepatol · review; journal article · DOI 10.1586/egh.13.6

Bibliografisk träff 2013-03-01

Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use.

Saadi M, McCallum RW.

Ther Adv Chronic Dis · research-article; journal article · DOI 10.1177/2040622312472008

Bibliografisk träff 2013-02-08

Antibiotics for the treatment of hepatic encephalopathy.

Patidar KR, Bajaj JS.

Metab Brain Dis · research-article; review; journal article · DOI 10.1007/s11011-013-9383-5

Bibliografisk träff 2013-02-01

Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis.

Neff GW, Jones M, Jonas M, Ravinuthala R, Novick D, Kaiser TE, Kemmer N.

J Clin Gastroenterol · research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1097/mcg.0b013e318276be13

Bibliografisk träff 2013-01-01

▾Rifaximin for the treatment of travellers' diarrhoea?

Författaruppgift saknas

Drug Ther Bull · journal article · DOI 10.1136/dtb.2013.1.0156

Bibliografisk träff 2012-12-29

Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?

Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Vilstrup H.

Metab Brain Dis · review; journal article · DOI 10.1007/s11011-012-9372-0

Bibliografisk träff 2012-12-27

A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosis.

Donders GG, Guaschino S, Peters K, Tacchi R, Lauro V, VARIANT 1 Study Group.

Int J Gynaecol Obstet · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ijgo.2012.08.022